Background: Minimizing initial neonatal blood draws and their associated pain is important. The placenta has ample fetal blood that is otherwise discarded; obtaining admission laboratory evaluations from fetal umbilical venous blood (FUVB) may provide a suitable alternative. Objective: We hypothesized that obtaining an aerobic bacterial blood culture (BCX) and a complete blood count with manual differential (CBC/diff) from FUVB is feasible and yields results comparable to those obtained directly from the neonate. Study Design: BCX and CBC/diff were attempted on paired samples from FUVB (in the delivery room) and neonatal blood (shortly after NICU admission) of 110 patients. The paired t test, Pearson's correlation coefficient (R), and multivariable linear regression were used for data analysis. Results: Positive BCXs were found in 9 of 108 FUVB samples compared to 1 of 91 neonatal samples. Three out of 9 FUVB cultures were true pathogens, including 2 Escherichia coli and 1 viridans group streptococcus, all with negative corresponding paired neonatal cultures. There was 1 positive neonatal BCX, E. coli, with a negative paired FUVB culture. Neonatal hemoglobin (Hb), platelets (PLT), and white blood cells (WBC) all significantly (p < 0.0001) correlated with the paired FUVB samples (R = 0.50, 0.49, and 0.84, respectively). Hb, PLT, and WBC values were clinically comparable but statistically higher in neonatal blood (the differences were 2.3 g/dL, 30,000 cells/μL, and 2,800 cells/μL, respectively; p < 0.007 for all comparisons). Conclusions: FUVB is suitable for obtaining CBC/diff. FUVB is an appropriate second source for BCX as it yields additional true pathogens. Our findings may support the presence of "culture-negative sepsis" in some neonates.
Introduction
Approximately 550,000 infants are born preterm in the USA (< 37 weeks gestational age [GA]), with over 90,000 < 32 weeks GA who require prolonged hospitalization [1] . Currently, many infants admitted to the NICU undergo a complete blood count with differential DOI: 10.1159/000491993 (CBC/diff) and, when indicated, an aerobic blood culture (BCX), in addition to other tests. Approximately 1.5-5 mL of blood is needed to complete admission testing. Using the example of an extremely-low-birth weight (ELBW) infant weighing 700 g (blood volume ∼50 mL) [2] , the initial phlebotomy losses represent 3-10% of its blood volume. Given the increased risk for early-onset sepsis (EOS) in preterms [3, 4] , "ruling out sepsis" is a common reason for NICU admission. Signs of EOS are subtle; early and accurate detection leads to better outcomes. Many factors influence the yield of BCX [5] , but the most important one is blood volume [6, 7] . Furthermore, neonatal phlebotomy (venipuncture/arterial stick) is painful and difficult to perform [8] . Blood sampling via heel lance may be suitable for obtaining CBC but not for culturing; additionally, it is more painful than venipuncture [9] .
Therefore, it seems prudent to consider the placenta, an otherwise discarded tissue, with its abundant fetal blood as an alternative source for NICU admission laboratory testing. The practice is gaining momentum [10] [11] [12] [13] , but mostly through case-controlled studies [12] or before/after quality improvement programs [13] . Limited studies used a paired-sampling prospective design that included BCX [14] [15] [16] or focused on ill neonates [17] . We designed this study to include all NICU patients, with a particular focus on the yield of paired BCX from fetal umbilical venous blood (FUVB) and neonatal samples in addition to analyzing CBC/diff results.
Methods
This was a single-center, paired-sampling, prospective study conducted at the University of California Irvine Medical Center (Orange, CA, USA). All infants born in our hospital and admitted to the NICU within 1 h were eligible. The period of recruitment was April 1, 2014, to April 8, 2016 . To calculate the sample size, the study was powered to test the hypothesis that there were clinically significant differences in hemoglobin (Hb), white blood cell (WBC), and platelet (PLT) counts when drawn from FUVB. Like Carroll et al. [17] , we sought to reject this hypothesis, therefore demonstrating that FUVB is an acceptable alternative. Using an internal survey, the following differences were considered clinically significant: 3 g/dL (Hb), 40,000 cells/μL (PLT), and 3,000 cells/μL (WBC). Based on the recent literature [18] , we considered as normal ranges 12-20 g/dL (Hb), 110,000-400,000 cells/μL (PLT), and 5,000-29,000 cells/μL (WBC). With α < 0.05 and 90% power, a sample size of 13, 37, and 45, respectively, was required. Given the risks of clotting, PLT clumping, and technical difficulties, we sought to enroll 100 patients. NICU nurses and two fellows were trained to draw FUVB (from the umbilical vein or its tributaries near insertion into the placenta) using the method detailed previously [19] . Single K 2 EDTA Microtainer ® tubes (for CBC/diff) and single aerobic BACTEC FX BCX bottles (BD Biosciences, Franklin Lakes, NJ, USA) were used. Upon placental delivery, the nurse used sterile gloves and cleansed the placenta 3 times (at the point of umbilical cord insertion) with betadine. Using a 5-mL syringe/18-G needle, the umbilical vein was accessed and 3-5 mL of blood (0.5 mL for CBC, the rest for BCX) was collected. The time of sampling and the volume of blood injected into the BCX bottles was not recorded. FUVB sampling was generally completed within 20 min after birth.
Neonatal admission BCX (if indicated) and CBC were obtained per standard of care. Neonatal BCX was drawn from an umbilical arterial/venous catheter (UAC/UVC) at the time of insertion, a peripheral artery (PA), or a peripheral vein (PV). Admission neonatal CBC was drawn from an UAC, UVC, or PA or via capillary sampling. The source of collection was recorded. Per our NICU protocol, laboratory studies are completed within 1 h after admission; however, the exact time of neonatal sampling was not recorded. The time of receipt of all samples (FUVB and neonatal) by the laboratory was recorded. Delayed cord clamping or umbilical cord milking (DCC/UCM) was done sporadically (depending on the preference of the clinical care provider) during the study. DCC/UCM was recorded as a categorical variable (yes/no); the duration of DCC or the frequency of UCM was not recorded. However, our practice at the time of the study recommended DCC for 45-60 s or UCM 3 times.
FUVB and neonatal CBC were analyzed on the same instrument, a Beckman-Coulter UniCel ® DxH 800 Analyzer with a VCSn module (Beckman Coulter, Inc., Brea, CA, USA). The differential WBC count was confirmed manually as well as by review of the blood smear. With regard to hematological measurements, samples with fibrin strands seen in the blood smear were excluded from WBC and PLT analysis [17] . Samples that were clotted or had PLT clumps or fibrin strands were labelled as "damaged." For the purposes of statistical analysis of Hb, the sources were consolidated into umbilical (U = UAC or UVC), peripheral (P = PA or PV), or capillary (C). Similarly, the PLT and WBC sources were consolidated into central (UAC, UVC, PA, or PV) or capillary. The clinical care providers were blinded to the results from the FUVB.
Statistical Analysis
Pearson's correlation test coefficient (R) was used to assess the correlation between results from FUVB and those from neonatal blood. The paired t test was used to test whether the differences between neonatal and FUVB results were significant. The independent-sample t test, Wilcoxon rank-sum test, and χ 2 test were occasionally used, as appropriate, to test subgroup differences. A multivariable linear (MVL) regression model was used to assess the association between neonatal blood and FUVB measures, adjusting for other characteristics of the infant, mother, and blood samples. Final models were obtained by using backward variable selection based on minimizing Akaike's information criterion. SAS version 9.4 (SAS Institute, Cary, NC, USA) was used. Two-sided tests with p < 0.05 were considered statistically significant.
Results
We enrolled 110 subjects (Fig. 1) . Table 1 shows the maternal and infant demographics. Major demographics (such as birth weight and GA) were similar between the enrolled and the nonenrolled patients (data not shown). The median times for samples to be received by the laboratory were 24 min (IQR 15-42) for FUVB and 75 min (IQR 65-105) for neonatal samples. Sources for neonatal BCX were UAC (n = 14), UVC (n = 16), PA (n = 19), and PV (n = 42). Sources for admission neonatal CBC were UAC (n = 14), UVC (n = 14), PA (n = 14), and PV (n = 13 (12) VLBW, very-low-birth weight; ELBW, extremely-low-birth weight; GA, gestational age; SGA, small for GA; LGA, large for GA; ROM, rupture of membranes; GBS, group B streptococcus; DCC/ UCM, delayed cord clamping/umbilical cord milking. 14) or via capillary sampling (n = 40). The source was unknown for 3 samples. As shown in Figure 1 , there were 28% "damaged" samples from FUVB versus 16% among neonatal samples. The times FUVB was received by the laboratory were significantly different between "damaged" and "nondamaged" samples (median 21 vs. 31 min; p = 0.021).
Blood Culture
Positive BCX were found in 9 of 107 FUVB samples and in 1 of 91 neonatal samples (8.4 and 1.1%, respectively). Microorganisms recovered from FUVB samples included E. coli (n = 2), viridans group streptococci (VGS; n = 2), coagulase-negative staphylococci (n = 3), and mixed organisms (n = 2). Based on the clinical course of the infants, inflammatory markers (WBC, immature-tototal WBC ratio, and C-reactive protein), the speed of bacterial growth, placental histology of chorioamnionitis/funisitis, and consensus among the investigators, 3 of these cultures were considered real pathogens (Table 2 ; true positive rate of 3.3%) and the rest were contaminants. One neonatal BCX was positive for E. coli; its paired FUVB culture was negative. There were no contaminants among the neonatal BCX.
Complete Blood Count
Hemoglobin A significant correlation (Fig. 2a) was demonstrated between FUVB Hb and neonatal Hb. The neonatal Hb level was higher than the FUVB Hb level, with a mean difference of 2.3 g/dL (Table 3 ). MVL regression (Table  4) showed DCC/UCM and capillary source to be associated with higher neonatal Hb levels. There were 2 FUVB samples with a hematocrit (HCT) < 30%; their corresponding paired neonatal HCT values were normal. None of the FUVB samples had an HCT > 65%. As for the neonatal samples, there were no cases with an HCT < 30%, but 7 cases with an HCT > 65%; all except 1 sample were capillary specimens. No neonates needed treatment for polycythemia, as their repeat venous HCT was normal. If an FUVB HCT < 30% or > 65% was defined as abnormal, 2 out of the 81 FUVB samples would have required redrawing (2.7%). On the other hand, 7 of the 81 neonatal samples (8.6%) required redrawing for confirmation.
Platelet Count A significant correlation (Fig. 2b ) between FUVB and neonatal PLT was documented. Additionally, the neona- tal PLT count was higher than the FUVB PLT count, with a mean difference of 30,000 cells/μL (Table 3) . MVL regression (Table 4) found that Cesarean delivery, exposure to chorioamnionitis, and capillary source were associated with lower neonatal PLT counts. There were 9 FUVB samples with a PLT count < 50,000 cells/μL; all except 2 samples had paired neonatal PLT counts > 100,000 cells/ μL. On the other hand, no valid neonatal blood samples had PLT counts < 50,000 cells/μL (after excluding damaged samples). No samples (FUVB or neonatal) had PLT counts > 420,000 cells/μL. If FUVB were relied upon exclusively to assess PLT and if a count < 50,000 cells/μL were defined as abnormal/needing redraw, 9 out of 72 valid FUVB samples would have required redrawing (12.5%).
WBC, Absolute Neutrophil Count, and Immature/ Total WBC Ratio A significant correlation (Fig. 2c) was noted between FUVB and neonatal WBC. The neonatal WBC count was 2,800 cells/μL higher than the FUVB WBC count (Table  3) . MVL regression ( 
Discussion
Obtaining timely admission laboratory evaluations from NICU patients is necessary for optimal care. In this study of high-risk NICU patients, we have demonstrated that drawing FUVB was technically feasible. There were 28% "damaged" samples (mostly due to clotting), a rate that is comparable to that observed with neonatal sam- pling in this study and to those reported in the published literature (16-30%) [20, 21] . We believe that the frequency of "damaged" samples can be reduced by prompt collection of FUVB and transport to the laboratory.
To our knowledge, this is the first study to evaluate paired cultures from FUVB and neonatal blood of highrisk neonates including ELBW infants. We found truepositive cultures in 3 FUVB samples (2 E. coli and 1 VGS; 3.3%) with negative cultures in the corresponding neonatal samples. All of these infants had predisposing risk factors for EOS, were clinically ill, had laboratory evidence suggestive of EOS, and had placental histology showing severe chorioamnionitis/funisitis. With negative neonatal BCX, some neonatologists may consider these infants affected by "culture-negative sepsis." The reason for their "negative" neonatal BCX may include the small blood volume for culturing, compounded with low-grade bacteremia as a result of intrapartum antibiotic use.
E. coli is the most common pathogen associated with EOS in premature infants [4] ; it is very unlikely to be a contaminant in our patients. VGS is the second most common gram-positive organism to cause EOS [4] ; as seen in 1 of our patients, it has been associated with intraamniotic infection (and neonatal EOS) in mothers with premature rupture of membranes/preterm premature rupture of membranes [22] . As for the 1 true-positive culture in a neonatal sample (E. coli) with a negative paired FUVB culture, this belonged to a late-preterm infant born after artificial rupture of membranes for 24 h. It is possible that this newborn had had low-grade bacteremia at birth (hence the negative FUVB BCX) but continued bacterial multiplication resulted in a positive neonatal BCX 72 min later.
We acknowledge that 6 other cultures from FUVB grew microorganisms that were contaminants. The etiology of this is not clear; we used the same sterile/antiseptic technique for both FUVB and neonatal blood culturing, both procedures were conducted by the same NICU staff, and we had zero contamination from neonatal samples. However, we did not practice drying the placental surface first before applying betadine; we speculate that the wet placental surface could have diluted the antiseptic solution, rendering it less effective and resulting in a relatively high contamination rate.
Several studies [14-16, 23, 24] examined the utility of cord blood/FUVB for the detection of EOS using different techniques with a reported contamination rate ranging from 0% [14] to 12.5% [16] . Polin et al. [23] evaluated 200 cord samples (drawn from excised umbilical cord segments) with only 29 paired infant samples and found 6 positive cultures; only 1 was declared a true pathogen (α-hemolytic streptococcus). Beeram et al. [15] evaluated 200 term and preterm (34.4 ± 4.4 weeks GA) infants at risk for EOS. They identified 2 positive BCX in cord samples, one of them a pathogen (group B streptococcus) and the other a contaminant; they also recovered 2 positive BCX from neonatal samples, one of them a pathogen (E. coli) and the other a contaminant. More importantly, and similar to our finding and that of Herson et al. [24] , there was a discordance between true-positive cultures in cord blood and in neonatal blood, underscoring the importance of obtaining blood from both sources. Despite the contamination issue, cord blood/ FUVB offers advantages as a second source for culturing as it represents a "kinder/gentler approach" [25] , allows for larger blood volumes, and, as we and others have shown [15, 24] , identifies true pathogens not recovered by neonatal sampling.
Our data provide some support for the presence of "culture-negative sepsis," a problem that neonatologists face daily. If it is agreed that 4 neonates in our study had true EOS, a culture obtained from FUVB yields a sensitivity of 75%, a specificity of 94%, a positive predictive value of 33%, and a negative predictive value of 99% for identifying EOS. On the other hand, the corresponding values for a neonatal BCX are a sensitivity of 25%, a specificity of 100%, a positive predictive value of 100%, and a negative predictive value of 97%. Some may question whether the widespread use of FUVB for culturing, with its enhanced sensitivity to detecting EOS, would increase the utilization of antibiotics in NICU. This issue may be viewed negatively in the era of antibiotic stewardship. We argue that identifying true EOS with a positive culture and antibiotic sensitivities would lead to a focused, narrow-spectrum antibiotic utilization. Furthermore, identifying true EOS is likely to reduce frequent "serial" sepsis screening with CBC, C-reactive protein assessment, and other tests. Although the contamination rate was higher with FUVB, we contend that it is not too difficult to separate true pathogens from contaminants based on clinical, bacteriological, and other laboratory criteria (Table 2) . Moreover, we believe the contamination rate can be reduced with team training and optimizing the sampling method.
We demonstrated that neonatal admission Hb levels correlated well with but were higher than FUVB levels. This finding is in agreement with the published literature [12, [15] [16] [17] and with a naturally expected increase in Hb seen a few hours after birth [18] . The increase could be due to an intravascular concentration of blood received DOI: 10.1159/000491993 by placental transfusion and, in part, due to evaporative fluid losses. As expected, the increase was more pronounced when neonatal blood was obtained from a capillary source [26, 27] and by DCC/UCM [28, 29] . Our study is different in that DCC/UCM was performed on about 30% of the study infants, which may explain the more pronounced increase in Hb we saw compared to Carroll et al. [17] . We consider the FUVB measurement of Hb/ HCT to be more accurate than neonatal capillary measurement, as it avoids a false diagnosis of polycythemia. This concept may seem counterintuitive in the new era of DCC, where polycythemia is a concern; however, a recent meta-analysis of DCC found that the procedure increased the peak HCT by only 2.7% [28] . We propose that capillary source sampling is the leading cause of false diagnosis of polycythemia; use of FUVB will avoid it in the majority of cases. Furthermore, these infants are closely monitored in the NICU, and many will undergo a repeat CBC at 12-24 h, which makes missing true polycythemia unlikely.
We noted a good correlation and a marginal increase in admission neonatal PLT compared to FUVB, especially when the source of neonatal sampling was central. This small increase is in contrast to what has been reported by others [15] [16] [17] , since Carroll et al. [17] and RotshenkerOlshinka et al. [16] found no significant differences and Beeram et al. [15] reported a drop of about 14,000 cells/ μL. The reason for the small increase in neonatal PLT seen in our study is not clear; we speculate that it could be due to placental transfusion as well as evaporative fluid losses (making all blood components concentrated). Alternatively, the delay in obtaining FUVB samples may have resulted in falsely low PLT counts due to submicroscopic clotting not detected by review of blood smears. We made every effort to control for this issue by excluding damaged samples from analysis. The association between capillary sampling and low PLT seen in the regression model is well established [27, 30] . The link between Cesarean delivery and PLT is not clear; it could be due to the fact that operative deliveries are more common among mothers with preeclampsia, which in turn predisposes to neonatal thrombocytopenia [31] . Clinical chorioamnionitis predisposes to EOS, and thrombocytopenia is commonly associated with neonatal infections [32] . The need to redraw for low PLT (12.5%) is comparable to that reported by Carroll et al. [17] (∼10%).
Our finding that neonatal WBC counts correlate very well with and are higher than those in paired FUVB is in agreement with other reports [14] [15] [16] [17] . WBC and ANC increase rapidly after birth, reaching their peak at 6-12 h of life in term and older preterm infants and at up to 36 h in ELBW infants < 28 weeks GA [18] . We speculate that the increase in admission neonatal WBC is due to this natural phenomenon (neonatal samples were received ∼77 min after birth). Additionally, labor and delivery result in maternal physiological leukocytosis shortly after birth [22] ; it is unclear whether similar mechanisms are responsible for a rise in neonatal WBC/ANC. As expected, FUVB WBC and ANC were significantly higher in patients exposed to clinical chorioamnionitis and in those treated with antibiotics, indicating their ability to "screen" patients at risk for EOS.
The strengths of our study include its pragmatic and prospective design with paired sampling, a relatively large sample size, and the inclusion of MVL regression analysis. Although a pragmatic design may create a heterogeneous group of subjects and be viewed as a weakness, we consider it as a strength, since it makes our findings relevant to the "real world" of neonatology practice. Our study is the first to include linear regression modeling to identify the impact of several factors on CBC indices. The impact of other variables, including DCC/UCM, the source of collection, the mode of delivery, and the diagnosis at admission, may explain, in part, the weak correlation in CBC indices (especially Hb and PLT; R < 65) between FUVB and neonatal blood samples demonstrated in this study and in other studies [14] [15] [16] . The limitations include poor enrollment of patients, the presence of damaged samples, a probable delay in obtaining FUVB, and the presence of contamination. We believe some of the limitations (sampling delay/damaged samples/contamination) could be minimized by refining the methodology (drying the placental surface before sampling) and with team training.
Conclusions
FUVB is an acceptable source for CBC/diff in all NICU admissions. Hb, PLT, and WBC are generally lower when analyzed from FUVB, but the differences are not clinically significant. FUVB is a useful addition to neonatal blood culturing in EOS, as it yields additional true pathogens not recovered by standard methods. Utilization of FUVB for NICU admission laboratory evaluation decreases iatrogenic blood loss and produces results more quickly. Furthermore, the procedure does not interfere with DCC/UCM, an additional measure that boosts the neonatal blood volume and minimizes the impact of phlebotomy losses. Additional studies are needed, espe- cially on high-risk NICU patients, to validate the findings of this study and decrease the BCX contamination issue reported in this study and in other studies.
